Esperion Therapeutics (ESPR) said Monday it reached a settlement with Micro Labs USA and its affiliate, Micro Labs, resolving a patent dispute over a proposed generic version of its cholesterol-lowering drug, Nexletol.
Under the terms of the agreement, Micro Labs agreed not to market a generic version of Nexletol in the US before April 19, 2040, except under limited circumstances typically included in such settlements.
Esperion said the litigation it filed against Micro Labs has now been resolved. However, patent lawsuits against several other generic drugmakers, including Accord Healthcare, Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories (RDY), Hetero USA, MSN Pharmaceuticals, Renata, and Sandoz, remain ongoing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.